BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr.

波士顿，2024年1月18日（环球通讯社）--HilleVax，Inc.（纳斯达克：HLVX），一家专注于开发和商业化新型疫苗的临床阶段生物制药公司，今天宣布任命Sean McLoughlin为首席运营官。作为与Mr。

McLoughlin’s appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Lead, RSV at GSK.

麦克劳林（McLoughlin）的任命、联合创始人兼现任首席运营官阿迪蒂亚·科利（AdityaKohli）博士将继续担任公司的全职高管，担任首席商务官，负责业务发展和公司战略。McLoughlin先生在疫苗方面拥有三十年的商业和运营经验，最近担任葛兰素史克全球疫苗商业化领导者RSV。

In this capacity, he was responsible for the successful commercial launch of GSK’s RSV product AREXVY. Prior to that Mr. McLoughlin held the position of New Product Strategy Lead, Vaccines Business Unit at GSK. He previously served as GSK’s U.S. Launch Lead, Shingrix. Mr. McLoughlin was at GSK for over 25 years, during which he held various leadership positions of increasing responsibility.

在这个职位上，他负责葛兰素史克RSV产品AREXVY的成功商业发布。在此之前，McLoughlin先生担任葛兰素史克疫苗业务部门新产品战略主管。此前，他曾担任葛兰素史克在美国的上市负责人Shingrix。麦克劳林先生在葛兰素史克工作了25年多，在此期间，他担任了各种领导职位，职责越来越重。

“We are excited to welcome Sean to HilleVax’s executive team as we continue to progress NEST-IN1, our Phase 2b clinical trial of HIL-214 for the prevention of moderate-to-severe norovirus-related acute gastroenteritis,” said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax. “Sean’s deep experience in developing and launching vaccines will be instrumental to HilleVax as we advance HIL-214 towards commercialization.” “I am thrilled to join HilleVax at such an exciting time and look forward to supporting the progress of HIL-214 as the potential first approved vaccine for norovirus infection,” said Mr.

HilleVax董事长兼首席执行官Rob Hershberg博士说：“我们很高兴欢迎Sean加入HilleVax的执行团队，因为我们将继续推进NEST-IN1，这是我们的HIL-214 2b期临床试验，用于预防中重度诺如病毒相关性急性胃肠炎。”。“Sean在开发和推出疫苗方面的丰富经验将有助于HilleVax推动HIL-214走向商业化。”“我很高兴在如此激动人心的时刻加入HilleVax，并期待着支持HIL-214作为潜在的第一种经批准的诺如病毒感染疫苗的进展，”Mr。

McLoughlin. “I have greatly enjoyed and appreciated my many .

麦克劳林。“我非常享受和感激我的许多。